Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heat therapy for knee pain: new study tests Nerve-Burning procedure after failed replacements

NCT ID NCT05283889

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a procedure called genicular radiofrequency ablation can safely reduce persistent knee pain in people who still hurt more than a year after total knee replacement. The procedure uses heat to temporarily calm specific nerves around the knee. Half of the 44 participants will get the real procedure, and half will get a sham (fake) version, so researchers can see if the real treatment truly helps more than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Genicular radiofrequency ablation (a procedure that uses heat to calm pain-sensing nerves around the knee)
What this could lead to
If it works, this could offer a minimally invasive option to reduce chronic pain and improve function for people whose knee replacement still hurts.
What could go wrong
This is a small, early-stage trial with only 44 participants, so results may not apply to everyone. The procedure carries risks like nerve damage or infection, and the sham comparison means some benefit could be due to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \>1 year post TKA * persistent knee pain \> 4/10 in intensity on average over the prior week of one of the post-TKA knees * refractory to conventional treatment (i.e., physiotherapy, medication, etc.) * ≥80% pain relief with a single fluoroscopically guided local anesthetic block using 0.5 mL of 2% lidocaine for the medial and lateral branches of the nerve to the vastus intermedialis, nerve to the vastus lateralis\*, inferior medial genicular nerve, infrapatellar branch of the saphenous nerve, and the recurrent fibular nerve. 0.5 mL will be injected over 2 spots (1.5 cm apart) for each of the superior medial and lateral genicular nerves corresponding to the sites of the RF cannulae for the bipolar strip lesions. \*Blocks will be combined fluoroscopy/ultrasound guided. Exclusion Criteria: * Infection (peri-prosthetic, joint, systemic, skin/soft tissue overlying the knee to be treated) * Prosthetic loosening or failure, periprosthetic fracture * Severe psychiatric disorder * Non-genicular lower extremity pain source from the spine (i.e., radiculopathy or neurogenic claudication) or peripheral joints (i.e., hip osteoarthritis) * Peripheral vascular disease causing vascular claudication * Connective tissue/inflammatory joint disease/widespread soft tissue pain disorder * Poor tolerance of injection procedures (as observed from the prognostic local anesthetic blocks) * Allergy to local anesthetic, synovial expansion into the anticipated path(s) of the local anesthetic needle/RF cannula as determined by ultrasound scanning * Uncontrolled bleeding diathesis * Pregnancy * Pacemaker or neurostimulator * Inability to complete Patient-Reported Outcome Measures due to cognitive or language limitations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis, knee are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vivo Cura Health

    Calgary, Alberta, T2E2P5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.